Matrix metalloproteinase‐26 is expressed in human endometrium but not in endometrial carcinoma
Open Access
- 18 December 2002
- Vol. 97 (1) , 79-89
- https://doi.org/10.1002/cncr.11030
Abstract
BACKGROUND The human matrix metalloproteinase (MMP)-26, also called matrilysin-2 or endometase, has been isolated as a matrilysin (MMP-7) homolog. Matrix metalloproteinase-26 was expressed in tissue samples from the placenta and endometrial tumors and its expression may be related to the development of endometrial carcinomas. METHODS Total RNAs were isolated from 5 endometrial carcinoma cell lines, 36 normal endometrial tissue samples, 4 hyperplasia tissue samples, and from 24 endometrial carcinoma tissue samples. Reverse transcription-polymerase chain reation (RT-PCR) was performed to detect MMP-26 mRNA expression. To identify MMP-26 mRNA localization and protein expression, we performed in situ RT-PCR and immunohistochemistry, respectively. RESULTS Reverse transcription-polymerase chain reaction analysis revealed that MMP-26 mRNA was expressed in 24 of 36 normal human endometrial tissue samples. However, MMP-26 mRNA expression was not detected in endometrial carcinoma cell lines nor in endometrial carcinoma tissue samples except for one case. Western blot analysis showed similar results. In situ RT-PCR analysis revealed that MMP-26 expression was localized in the epithelial glandular cells but faint expression was observed in the stromal cells. Subsequently, we separated endometrial tissues into epithelial glandular and stromal cells. Using RT-PCR, the purified epithelial glandular cells exhibited MMP-26 mRNA expression but the purified stromal cells did not. Immunohistochemical analyses revealed that MMP-26 protein expression is also limited to endometrial epithelial glandular cells but not to cancer cells. Therefore, MMP-26 expression is limited to normal epithelial glandular cells. CONCLUSIONS We found a significant difference in MMP-26 expression in normal and malignant endometrial tissue samples, although its function is still unknown. These data suggest that MMP-26 may be a candidate for a new tumor marker for endometrial carcinomas. Cancer 2003;97:79–89. © 2003 American Cancer Society. DOI 10.1002/cncr.11030Keywords
This publication has 20 references indexed in Scilit:
- Identification and Characterization of Human Endometase (Matrix Metalloproteinase-26) from Endometrial TumorJournal of Biological Chemistry, 2000
- Cloning of MMP‐26European Journal of Biochemistry, 2000
- Membrane‐type matrix metalloproteinasesAPMIS, 1999
- Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family MembersJournal of Biological Chemistry, 1999
- The Papanicolaou Smear: Its Impact on the Promotion of Women’s HealthJournal of Obstetric, Gynecologic & Neonatal Nursing, 1998
- Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancerNature Medicine, 1996
- Tumor Cell Interactions with the Extracellular Matrix During Invasion and MetastasisAnnual Review of Cell Biology, 1993
- A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometryAmerican Journal of Obstetrics and Gynecology, 1989
- KLE: A cell line with defective estrogen receptor derived from undifferentiated endometrial cancerGynecologic Oncology, 1984
- Metabolism and effects of progesterone in the human endometrial adenocarcinoma cell line HEC-1Steroids, 1980